 | Up a level |
Flammer, A.J.; T.Vo, N.T.; Ledergerber, B; Hermann, F; Gamperli, A; Huttner, A; Evison, J; Baumgartner, I; Cavassini, M; Hayoz, D.; Quitzau, K; Hersberger, M; Sudano, I; Ruschitzka, F; Luscher, T.F.; Noll, G; Weber, R. (2009). Effect of atazanavir versus other protease inhibitor-containing antiretroviral therapy on endothelial function in HIV-infected persons: randomised controlled trial. Heart, 95(5), pp. 385-90. London: BMJ Publishing Group 10.1136/hrt.2007.137646
Koskinas, K C; Gencer, B.; Raeber, L; Karagiannis, A.; Nanchen, D.; Carballo, D.; Carballo, S.; Klingenberg, R.; Heg, D; Matter, C.; Luscher, T.F.; Rodondi, N; Windecker, S; Mach, F. (August 2017). P169 Eligibility for PCSK9 inhibitors according to ESC/EAS and ACC recommendations after acute coronary syndromes. European Heart Journal, 38(suppl_1), ehx501.P169. Oxford University Press 10.1093/eurheartj/ehx501.P169
